Exelixis EXEL Accrued clinical trial liabilities
Accrued clinical trial liabilities at other companies
Other financials
Where this comes from
Reported directly by Exelixis in its filing.
Tagged under the XBRL concept exel:AccruedClinicalLiabilitiesCurrent.
The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Exelixis's accrued clinical trial liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Exelixis's accrued clinical trial liabilities?
- Exelixis (EXEL) reported accrued clinical trial liabilities of $64.8M in Q1 2026.
- How has Exelixis's accrued clinical trial liabilities changed year-over-year?
- Exelixis's accrued clinical trial liabilities increased by 12.4% year-over-year, from $57.64M to $64.8M.
- What is the long-term trend for Exelixis's accrued clinical trial liabilities?
- Over 5 years (2020 to 2025), Exelixis's accrued clinical trial liabilities has grown at a 4.7% compound annual growth rate (CAGR), from $52.25M to $65.74M.
- What does accrued clinical trial liabilities mean?
- The estimated unpaid costs for clinical research and trial activities currently in progress.
- How do you interpret accrued clinical trial liabilities?
- An increase indicates active, ongoing clinical trial enrollment and research activity, while a decrease may signal the completion of trials or a slowdown in R&D investment.
- How does accrued clinical trial liabilities compare across companies?
- Specific to clinical-stage biopharma; peers with large, late-stage trial portfolios will show higher balances here.